1 / 60

Director’s Report to the National Advisory Council on Drug Abuse

Director’s Report to the National Advisory Council on Drug Abuse. February 8, 2006. Director’s Report to the National Advisory Council on Drug Abuse. Budget Update. What’s New @ NIH?. Recent NIDA Activities. Science Findings. Budget Update. NIDA BUDGET. (Thousands). 2007 PB.

belva
Download Presentation

Director’s Report to the National Advisory Council on Drug Abuse

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Director’s Report to the National Advisory Council on Drug Abuse February 8, 2006

  2. Director’s Report to the National Advisory Council on Drug Abuse Budget Update What’s New @ NIH? Recent NIDA Activities Science Findings

  3. Budget Update

  4. NIDA BUDGET (Thousands) 2007PB 2005Actual 2006Approp. $693,282 $699,956 $695,563 $299,266 $994,829 NonAIDS $313,137 $300,073 AIDS $1,006,419 $1,000,029 TOTAL Increase Over Prior Year +1.2% -0.6% -0.5%

  5. What’s New @ NIH?

  6. First Major Independent Research Support Occurs at an Ever-Later Age Average Age of Initial Type 1 R01/R23/R29 Award for Different Degrees Held 45 44 44 43 42 42 M.D.-Ph.D. 41 M.D. Average age 40 40 Ph.D. 39 38 38 37 37 36 35 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 Fiscal Year For more information, see http://grants.nih.gov/grants/20040712_New_Investigator_Talk.ppt

  7. New Investigators Program NIH is Committed to Providing Pathways to Research Independence For New Investigators Pathway to Independence Award NRSA Individual and Institutional Training Awards Career Development Awards Research Project Grant Program NIH Institute and Center Practices Resources for New Investigators NIH Pathway to Independence Award Program • Announced January 27, 2006 • Opportunity for promising postdoctoral scientists to receive both • mentored and independent research support from the same award • Responsive to NAS 2005 Report “Bridges to Independence” • Beginning in Fall 2006 NIH plans to issue 150 to 200 awards/year • for the next 5 years

  8. ENHANCING THE VITALITY OF THE NATIONAL INSTITUTES OF HEALTH: Organizational Change to Meet New Challenges NATIONAL ACADEMY OF SCIENCES INSTITUTE OF MEDICINE Recommendations Focused On OptimizingFunction Rather Than Changing Structure The NIH Office of Portfolio Analysis & Strategic Initiatives (OPASI)

  9. Why Does NIH Need OPASI? • Need for coordinated assessment and management of the overall portfolio of NIH-funded research • Need for transparent, systematic processes for: • Coding of specific diseases and conditions • Assessing scientific opportunities and public health needs and integrating them into NIH-wide funding priorities • Coordinating funding of research areas that cut across or fall between the missions of individual Institutes and Centers

  10. How Does OPASI Select and Implement Trans-NIH Research? • Proposals are reviewed by: • OPASI leadership • Institute and Center (IC) Directors • Council of Councils • Advisory Committee to the Director (ACD) • NIH Director • Once approved for funding: • Initiatives are assigned to a lead IC or ICs • Research is supported by the Common Fund

  11. Common Fund for Shared Needs • Fund initiatives that are in areas of interest to multiple ICs • Current Roadmap funds will serve as the baseline for the Common Fund: 1.1% of the total NIH budget in FY 2006, growing to ~1.7% in FY 2008 • Future growth of the Common Fund: • No growth above the FY 2008 percent until the annual NIH budget increase exceeds Biomedical Research and Development Price Index (BRDPI) • Rate of growth will be determined annually by NIH Director and IC Directors • Common Fund will increase up to 5% of the total NIH budget

  12. Recent NIDA Activities

  13. NIDA Council Workgroups

  14. NIDA Basic Science Review Workgroup First Meeting November 17-18, 2005 Second Meeting March 2006 NIDA Council Members Linda Porrino, Ph.D, Chair Barry Lester, Ph.D. John P. Rice, Ph.D. Frank Ivy Carroll, Ph.D Yasmin Hurd, Ph.D. Guy Cabral, Ph.D. Stanley Watson, M.D., Ph.D. Marina Picciotto, Ph.D. Michael Nader, Ph.D. Kathryn Cunningham, Ph.D.

  15. NIDA Basic Science Review Workgroup Charge: To produce a written report that includes… • Review of the current Basic Science program portfolio • Recommendations to strengthen the current program • Input into the 5-year plan for NIDA’s Basic Science program • with an emphasis on: • Genetic vulnerability and protection • Epigenetics (interactions of environment and genetics) • The genetics and neurobiology of social behavior • Molecular biology of addiction • Examination of the organization and management of DNBR and its interactions with other NIDA Divisions/Centers

  16. NIDA’s Approach to Grant-Making Work Group First Meeting December 6-7, 2005 Second Meeting February 7, 2006 NIDA Council Members Scott Lucas, Ph.D. Kathleen Carroll, Ph.D. Tom Kosten, M.D. Constance Weisner, Dr.P.H., M.S.W., Chair David Vlahov, Ph.D. Claire E. Sterk, Ph.D. Mark Greenberg, Ph.D. Rodolfo Arredondo, Jr., Ed.D. Linda Porrino, Ph.D.

  17. NIDA’s Approach to Grant-Making Work Group Charge: To produce a written report and determine if any actions or new policies may be needed on the following… • Recommendations to ensure that in this age of restricted • budgets we protect young investigators • Balance between “large” versus “small” science at NIDA • Guidelines regarding PI with multiple grants (NIDA or other • IC) or laboratories with multiple grants • Recommendations regarding length of duration of grants • (R01s, Centers, program projects)

  18. Social Neuroscience (RFA-DA-06-004) (With Canadian Institutes of Health Research (CIHR)) Released November 10, 2005 Application receipt Date: February 23, 2006

  19. Prescription Opioid Use and Abuse in the Treatment of Pain (RFA-DA-06-005) (with NIA and NIDCR) Released November 18, 2005 Application Receipt Date: February 23, 2006

  20. PAs and RFAs Issued With Other NIH Components/Agencies 29 New PAs and 11 New RFAs • Foci include: • Neuroimaging • HIV/AIDS • Biotechnology • Dissemination & Implementation • Research Training

  21. NIDA National Institute on Drug Abuse Office of the Director Nora D. Volkow, MD Director Director, AIDS Research HIV/AIDS Research Special Populations Office Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Office of Extramural Affairs Office of Planning & Resource Management Office of Science Policy & Communications Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program Division of Clinical Neuroscience & Behavioral Research David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  22. HIV/AIDS and Drug Abuse: The Complexities of Linked Epidemics Press Conference & Science Meeting National Press Club November 29, 2005

  23. NIDA National Institute on Drug Abuse Office of the Director Nora D. Volkow, MD Special Population/ Health Disparities Director Director, AIDS Research Special Populations Office Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Office of Extramural Affairs Office of Planning & Resource Management Office of Science Policy & Communications Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program Division of Clinical Neuroscience & Behavioral Research David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  24. National Institute on Drug Abuse Health Disparities Conference • Nearly 400 participants • Plenary sessions addressed • HIV/AIDS • Criminal Justice Concerns • Other Issues in Health • Disparities Research Related • to Drug Use • Meeting Outcomes included: • Discussion of collaborations between investigators, • Established mentorship with students • Increased awareness of opportunities with NIDA • through grant development workshops

  25. Administrative Supplements for Research on the Intersection of Drug Use and Criminal Justice Consequences in the African American Population 6 Supplements Awarded Health Disparities in HIV/AIDS: Focus on African Americans (R01) (PA-06-069) (with NIMH) Released November 10, 2005 Drug Abuse as a Cause, Correlate, or Consequence of Criminal Justice Related Health Disparities Among African Americans (R01) (PA-06-068) Released November 10, 2005

  26. NIDA National Institute on Drug Abuse Office of the Director Nora D. Volkow, MD Director Director, AIDS Research Special Populations Office Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Office of Extramural Affairs Office of Planning & Resource Management Office of Science Policy & Communications Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Division of Clinical Neuroscience & Behavioral Research Intramural Research Program DPMCDA David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  27. Design, Synthesis and Preclinical Testing of Potential Treatment Agents for Drug Addiction (PAS-06-066) Released November 9, 2005

  28. Methylphenidate p=0.0142 3 1 -1 -3 Proportion of Amphetamine Positive Urines During the 12-Week Period Placebo p=0.7869 5 10 15 20 3 1 -1 -3 5 10 15 20 Methylphenidate Was Associated With Significantly Better Outcomes Than Placebo Source: Tiihonen, J. presented at NIDA-sponsored meeting “The Methamphetamine Menace” December 10, 2005.

  29. NIDA National Institute on Drug Abuse Office of the Director Nora D. Volkow, MD Director Director, AIDS Research Special Populations Office Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Office of Extramural Affairs Office of Planning & Resource Management Office of Science Policy & Communications Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program Division of Clinical Neuroscience & Behavioral Research DBNBR David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  30. Epigenetics of Neurobiology and Addiction (RFA-DA-06-007) (With Canadian Institutes Of Health Research (CIHR)) Released October 2, 2005 Application Receipt Date: January 23, 2006

  31. NIDA National Institute on Drug Abuse Office of the Director Nora D. Volkow, MD Director Director, AIDS Research Special Populations Office Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Office of Extramural Affairs Office of Planning & Resource Management Office of Science Policy & Communications Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program Division of Clinical Neuroscience & Behavioral Research DESPR David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  32. Issues of Concern Percent of 12th Graders Reporting Nonmedical Use of OxyContin and Vicodin in the Past Year Remained High 12.0 10.5 9.5 9.6 9.3 10.0 8.0 Percent 6.0 5.5 5.0 4.5 4.0 4.0 2.0 0.0 OxyContin* Vicodin 2002 2003 2004 2005 No year-to-year differences are statistically significant. * Between 2002 and 2005 the abuse of OxyContin by 12th graders increased significantly.

  33. NIDA National Institute on Drug Abuse Office of the Director Nora D. Volkow, MD Director Director, AIDS Research Special Populations Office Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Office of Extramural Affairs Office of Planning & Resource Management Office of Science Policy & Communications Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program Division of Clinical Neuroscience & Behavioral Research DCNBR David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  34. Developmental Centers for Translational Research on the Clinical Neurobiology of Drug Addiction (P20) (RFA-DA-06-006) Released November 8, 2005 Application Receipt Date: February 23, 2006

  35. Imaging – Science Track Award for Research Transition (I/START) (R03) (PAR-06-092) Released December 9, 2005

  36. NIDA National Institute on Drug Abuse Office of the Director Nora D. Volkow, MD Director Director, AIDS Research Special Populations Office Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Office of Extramural Affairs Office of Planning & Resource Management Office of Science Policy & Communications Center for the Clinical Trials Network CCTN Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program Division of Clinical Neuroscience & Behavioral Research David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  37. Update on New CTN Protocols • 1. Starting Treatment with Agonist Replacement Therapies (START): compare the effect of buprenorphine/naloxone • and methadone on liver function 10 sites, April 2006 • 2. Prescription Opioid Addiction Treatment Study (POATS) • ~ 12 sites, Spring 2006 • Randomized Controlled Trial of Methylphenidate in • Adolescents with ADHD and Substance Use Disorders • 10 sites,February 2006 • 4. Methylphenidate in Maintaining Abstinence in Smokers • with ADHD 6 sites, 255 pre-screened; 52 consented; 16 randomized • Protocol to assess the utility of 12-Step Facilitation in • increasing 12-Step participation and improving drug abuse treatment outcomes (in cocaine and meth abusers) under development

  38. Update on NIH & NIDA Initiatives

  39. NIH Roadmap ACCELERATING MEDICAL DISCOVERY TO IMPROVE HEALTH NIH Roadmap Activities

  40. Exploring NIDA’s Opportunities in the NIH Roadmap Molecular Libraries Project October 18 and 19, 2005 • Primary Recommendations: • Improve public relations for the • Molecular Library/Molecular Imaging (ML/MI) Program • Provide incentives for participation in the initiatives

  41. Integration of Clinical Research Networks • Clinical Research Training and Career Development • Harmonization of Clinical Research Policy • Institutional Clinical and Translation Science Awards • Interdisciplinary Research (within the Roadmap • theme: Research Teams of the Future)

  42. LNI for Neuroscience Research Neuroscience Information Framework NIH Goal: To develop a comprehensive, dynamic inventory of Web-accessible neuroscience information resources that span multiple levels of biological function Laboratory of Neuroinformatics Weill Medical College of Cornell University SOCIETY FOR NEUROSCIENCE PI -- Daniel Gardner • Five Groups – at Caltech, Cornell, UCSD, George Mason, • and Yale– have partnered with the SfN and with volunteer • collaborators at nine additional sites to develop: • The Framework • Terminology/Ontology for neuroscience • A content-based query tool Phase I began September 30, 2005

  43. for Neuroscience Research RFAs Neuroscience Blueprint Interdisciplinary Center Core Grants (RFA-NS-06-003) -- Issued: September 29, 2005; Application Receipt Date: January 19, 2006 Development of Recombinase-Expressing (“Driver”) Mouse Lines for Studying the Nervous System (U01) (RFA-MH-06-007) Issued November 18, 2005; Application Receipt Date: January 19, 2006 Training in Translational Research in Neurobiology of Disease (T32) (RFA-DA-06-008) -- Issued November 9, 2005; Application Receipt Date: February 22, 2006 Training in Computational Neuroscience: From Biology to Model and Back Again (T90) (RFA-DA-06-101) Issued: December 16, 2005; Application Receipt Date: March 13, 2006 Training in Neuroimaging: Integrating First Principles and Applications (T90) (RFA-DA-06-011) Issued December 23, 2005; Application Receipt Date: March 13, 2006

  44. Primary Care Physicians Are Often Reluctant To Treat Substance Abuse or Fail to Link This With Their Patients’ Other Medical Conditions • Mental Illness • Cancer • Infectious Diseases • (HIV, HCV) • Cardiac • Pulmonary • Learning Disorders • Obesity • Cerebrovascular (strokes) • Trauma (accidents)

  45. NIDA’s Primary Care Outreach Initiative • Physician Work Group • Establishedto help us craft • our activities in this area • Workgroup Meeting Held January 27, 2006 • Physicians’ Page • Added to our Website

  46. and NIDA NATIONAL INSTITUTE ON DRUG ABUSE Opportunities for Collaboration • Create an Interagency Workgroup between • FDA and NIDA • Re-establish a body of drug abuse expertise • similar to the former FDA Drug Abuse Advisory • Council (DAAC) chartered from 1978-2002

  47. Recent Meetings, Conferences and Events

  48. Addiction and Obesity – Brain Systems Commonalities Presentation by the Jacob A. Waletzky Award Recipient Neurobiological Basis for Co-occurring Substance Abuse & Mental Illness Poster Session: Early Career Investigators mGluR: A Substrate in the Neurobiology of Addiction Reconsolidation of Memory: A New Approach to Treat Drug Addiction? Adolescent Drug Abuse: Brain Development, Cognition & Vulnerability November 11, 2005 -- 8:00AM to 9:00PM

More Related